Improved hepatitis A and hepatitis B vaccination strategy is necessary for patients with chronic hepatitis C

Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities

“…Amidst these challenges, vaccine hesitancy remains a formidable barrier to achieving comprehensive immunization coverage within this patient group. Factors contributing to this hesitancy include socioeconomic disparities, fears regarding adverse effects, and skepticism about vaccine efficacy, necessitating targeted communication strategies and evidence-based interventions to mitigate these concerns [ 6 ]. Despite the general advocacy for vaccinations against influenza, pneumococcal disease, and viral hepatitis among CLD patients, there is a notable deficiency in systematic evaluations of vaccine efficacy specifically within this demographic with much of the supporting evidence extrapolated from studies on other immunocompromised populations [ 7 ].…”

Avaliação da imunogenicidade anti-HBV em portadores crônicos do vírus da hepatite C não cirróticos após exposição a dois esquemas de vacina contra hepatite B

“…No estudo de Maqsood et al 85 A obesidade é o maior fator de risco para o desenvolvimento de diabetes mellitus tipo 2; 53% dos adultos com diabetes são obesos 98 .…”